A new model created by Melanoma Institute Australia (MIA), further described and discussed in a recent issue of the Journal of Clinical Oncology, has been shown to "predict recurrence-free survival and overall survival in patients with a primary cutaneous melanoma considerably better" than what is described in cancer staging manuals. Study authors further concluded that the MIA model can be used in daily practice without the need to conduct sentinel node biopsy, even for high-risk patients.
To learn more about the MIA model, click here.
Study mentioned:
Varey AHR, Li I, El Sharouni M-A, et al. Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator. JCO; Published online 5 February 2024. DOI: https://doi.org/10.1200/JCO.23.01020
No comments:
Post a Comment